미국의 욕창 치료 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 임상 중증도별, 최종 용도별 및 부문별 전망(2026-2033년)

U.S. Pressure Ulcer Treatment Market Summary

The U.S. pressure ulcer treatment market size was valued at USD 2.3 billion in 2025 and is projected to grow from USD 2.4 billion in 2026 to USD 3.4 billion by 2033, at a CAGR of 5.4% from 2026 to 2033. The growth of the U.S. pressure ulcer treatment market is driven by the persistent burden of pressure injuries among hospitalized and long-term-care patients, increasing focus on pressure injury prevention and quality outcomes, rising adoption of advanced wound-care technologies, and growing demand for specialized treatment across hospitals, skilled nursing facilities, and home healthcare settings.

The continuing burden of pressure injuries is increasing demand for effective wound-care and treatment solutions across U.S. healthcare settings. For instance, AHRQ Network of Patient Safety Databases Chartbook, 93,807 pressure injury events were reported through December 2024. Among the 17,077 events with valid information on the most advanced stage, 66.6% (11,377 cases) were deep tissue pressure injuries, 10.2% (1,748 cases) were Stage 3, and approximately 21.1% (3,600 cases) were unstageable. The report also found that 77.1% of 17,936 reported events involved patients who had received a preventive intervention, indicating that pressure injuries continue to occur despite preventive measures. Furthermore, 63.8% of reported cases developed a secondary morbidity or had an unknown outcome, while Stage 4 injuries showed the highest reported harm rate at 82%. The substantial number of advanced and potentially harmful pressure injuries supports continued demand for advanced dressings, negative pressure wound therapy, pressure-relieving systems, and other treatment solutions.

Clinical Trials Landscape

Clinical trials are supporting innovation in the U.S. pressure ulcer treatment market by generating clinical evidence on advanced biological therapies for severe and nonhealing wounds. Research is focused on cellular, acellular, and matrix-like products that can accelerate wound closure and improve outcomes in patients with difficult-to-heal Stage III and Stage IV pressure ulcers. For instance, in May 2025, Tiger Biosciences, LLC initiated the Phase 4 NCT06999590 clinical trial in the U.S. to evaluate several cellular, acellular, and matrix-like products (CAMPs), including ACApatch and caregraFT, in combination with standard wound care for nonhealing pressure ulcers. The multicenter, prospective, randomized controlled modified platform trial plans to enroll approximately 500 adult patients with chronic Stage III or Stage IV pressure ulcers. The study will compare weekly applications of these biological products plus standard care with matched standard-of-care controls, with complete wound closure serving as the primary outcome. The trial is expected to be completed in May 2027. The study highlights the growing development of advanced biological and regenerative wound-care therapies and is expected to strengthen clinical evidence supporting the adoption of active & bio-therapies, particularly cellular, acellular, and matrix-based products, in the U.S. pressure ulcer treatment market.

U.S. Pressure Ulcer Treatment Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pressure ulcer treatment market report based on product, clinical severity, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Wound Care Dressings
  • Moist
  • Foam Dressings
  • Hydrocolloid Dressings
  • Film Dressings
  • Alginate Dressings
  • Hydrogel Dressings
  • Collagen Dressings
  • Other Advanced Dressing
  • Antimicrobials
  • Silver
  • Non-silver
• Active & Bio-Therapies
  • Active Biomaterials
  • Bioengineered Skin Substitutes
  • Growth Factors
• Wound Care Devices & Systems
  • Negative Pressure Wound Therapy (NPWT)
  • Pressure Redistribution & Support Surfaces
  • Hyperbaric Oxygen Equipment
  • Electrical Stimulation Devices
• Topical & Pharmacological Agents
  • Debriding Agents
  • Topical Antimicrobials & Antiseptics
• Other Treatment Products
  • Offloading & Positioning Devices
  • Wound Cleansing & Irrigation Products
• Clinical Severity Outlook (Revenue, USD Million, 2021 - 2033)
• Stage I
• Stage II
• Stage III
• Stage IV
• Deep Tissue Injury (DTI)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Acute Care Hospital
• Long-term Acute Care Hospital
• Burn Center
• Ambulatory Surgery Center
• Hospital Outpatient Department Wound Care Clinic
• Inpatient Rehabilitation Facility
• Skilled Nursing Facility
• Long-term Care (living setting)
• Physician Office
• Home Healthcare

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in U.S.
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Pressure Ulcer Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising pressure-injury burden among aging and high-risk patients
    • 3.2.1.2. Growing hospital focus on pressure-ulcer prevention and quality outcomes
    • 3.2.1.3. Increasing use of advanced wound-care products
    • 3.2.1.4. Rising demand for chronic and complex wound treatment
    • 3.2.1.5. Expansion of evidence-based wound-care protocols
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Improved prevention reducing treatment demand
    • 3.2.2.2. Limited evidence for some advanced therapies
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Expansion of home-based wound care
    • 3.2.3.2. AI-enabled early detection and risk prediction
    • 3.2.3.3. Growth of portable and disposable NPWT
    • 3.2.3.4. Digital wound monitoring and smart sensors
    • 3.2.3.5. Increasing value-based wound-care models
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Variability in wound staging and documentation
    • 3.2.4.2. Need to demonstrate clinical and cost effectiveness
• 3.3. U.S. Pressure Ulcer Treatment Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. U.S. Pressure Ulcer Treatment Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Pressure Ulcer Treatment Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. U.S. Pressure Ulcer Treatment Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Wound Care Dressings
  • 4.4.1. Wound care dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Moist
    • 4.4.2.1. Moist market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.2. Foam Dressings
      • 4.4.2.2.1. Foam dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.3. Hydrocolloid Dressings
      • 4.4.2.3.1. Hydrocolloid dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.4. Film Dressings
      • 4.4.2.4.1. Film dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.5. Alginate Dressings
      • 4.4.2.5.1. Alginate dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.6. Hydrogel Dressings
      • 4.4.2.6.1. Hydrogel dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.7. Collagen Dressings
      • 4.4.2.7.1. Collagen dressings market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.8. Other Advanced Dressing
      • 4.4.2.8.1. Other advanced dressing market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Antimicrobials
    • 4.4.3.1. Antimicrobials market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Silver
      • 4.4.3.2.1. Silver market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.3. Non-silver
      • 4.4.3.3.1. Non-silver market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Active & Bio-Therapies
  • 4.5.1. Active & bio-therapies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Active Biomaterials
    • 4.5.2.1. Active biomaterials market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Bioengineered Skin Substitutes
    • 4.5.3.1. Bioengineered skin substitutes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Growth Factors
    • 4.5.4.1. Growth factors market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Wound Care Devices & Systems
  • 4.6.1. Wound care devices & systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Negative Pressure Wound Therapy (NPWT)
    • 4.6.2.1. Negative pressure wound therapy (NPWT) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Pressure Redistribution & Support Surfaces
    • 4.6.3.1. Pressure redistribution & support surfaces market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Hyperbaric Oxygen Equipment
    • 4.6.4.1. Hyperbaric oxygen equipment market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Electrical Stimulation Devices
    • 4.6.5.1. Electrical stimulation devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Topical & Pharmacological Agents
  • 4.7.1. Topical & pharmacological agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Debriding Agents
    • 4.7.2.1. Debriding agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. Topical Antimicrobials & Antiseptics
    • 4.7.3.1. Topical antimicrobials & antiseptics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Other Treatment Products
  • 4.8.1. Other treatment products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8.2. Offloading & Positioning Devices
    • 4.8.2.1. Offloading & positioning devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8.3. Wound Cleansing & Irrigation Products
    • 4.8.3.1. Wound cleansing & irrigation products market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Pressure Ulcer Treatment Market: Clinical Severity Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Pressure Ulcer Treatment Market: Clinical Severity Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. U.S. Pressure Ulcer Treatment Market Size & Trend Analysis, by Clinical Severity 2021 to 2033 (USD Million)
• 5.4. Stage I
  • 5.4.1. Stage I market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Stage II
  • 5.5.1. Stage II market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Stage III
  • 5.6.1. Stage III market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Stage IV
  • 5.7.1. Stage IV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Deep Tissue Injury (DTI)
  • 5.8.1. Deep tissue injury (DTI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Pressure Ulcer Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Pressure Ulcer Treatment Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. U.S. Pressure Ulcer Treatment Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Acute Care Hospital
  • 6.4.1. Acute care hospital market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Long-term Acute Care Hospital
  • 6.5.1. Long-term acute care hospital market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Burn Center
  • 6.6.1. Burn center market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Ambulatory Surgery Center
  • 6.7.1. Ambulatory surgery center market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. Hospital Outpatient Department Wound Care Clinic
  • 6.8.1. Hospital outpatient department wound care clinic market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.9. Inpatient Rehabilitation Facility
  • 6.9.1. Inpatient rehabilitation facility market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.10. Skilled Nursing Facility
  • 6.10.1. Skilled nursing facility market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.11. Long-term Care (living setting)
  • 6.11.1. Long-term care (living setting) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.12. Physician Office
  • 6.12.1. Physician office market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.13. Home Healthcare
  • 6.13.1. Home healthcare market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis, 2025
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
  • 7.5.1. Expansion
  • 7.5.2. Mergers & Acquisition
  • 7.5.3. Partnerships & Collaborations
  • 7.5.4. New Technology Launches
  • 7.5.5. Research And Development
  • 7.5.6. Company Profiles
  • 7.5.7. SYST'AM
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Ulcer Solutions, LLC.
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Stryker
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Baxter (Hillrom)
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. Arjo
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. LINET
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. Invacare Corporation
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. 3M
    • 7.5.14.1. Company overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. Smith+Nephew
    • 7.5.15.1. Company overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic initiatives
  • 7.5.16. Molnlycke AB
    • 7.5.16.1. Company overview
    • 7.5.16.2. Financial performance
    • 7.5.16.3. Product Benchmarking
    • 7.5.16.4. Strategic initiatives
  • 7.5.17. Savaria
    • 7.5.17.1. Company overview
    • 7.5.17.2. Financial performance
    • 7.5.17.3. Product Benchmarking
    • 7.5.17.4. Strategic initiatives
  • 7.5.18. Joerns Healthcare
    • 7.5.18.1. Company overview
    • 7.5.18.2. Financial performance
    • 7.5.18.3. Product Benchmarking
    • 7.5.18.4. Strategic initiatives
  • 7.5.19. B. Braun SE
    • 7.5.19.1. Company overview
    • 7.5.19.2. Financial performance
    • 7.5.19.3. Product Benchmarking
    • 7.5.19.4. Strategic initiatives
  • 7.5.20. Medline
    • 7.5.20.1. Company overview
    • 7.5.20.2. Financial performance
    • 7.5.20.3. Product Benchmarking
    • 7.5.20.4. Strategic initiatives
  • 7.5.21. Convatec
    • 7.5.21.1. Company overview
    • 7.5.21.2. Financial performance
    • 7.5.21.3. Product Benchmarking
    • 7.5.21.4. Strategic initiatives